Molecular Analysis of Isoleucyl-tRNA Synthetase Mutations in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus with Low-Level Mupirocin Resistance by Yang, Jin Ah et al.
INTRODUCTION
Methicillin-resistance Staphylococcus aureus (MRSA) has been
a major cause of nosocomial infections and has been isolated
with increasing frequency from patients in hospitals and nurs-
ing homes (1). Nasal and extranasal carriage of MRSA is an
essential step in invasive MRSA infections and plays a deci-
sive role in the dissemination of these microorganisms (2).
Topical mupirocin has been widely used for managing
MRSA infections, reducing certain types of surgical site infec-
tions, and clearing nasal MRSA carriage, especially among
healthcare workers. In 1987, shortly after the introduction
of mupirocin, clinical isolates of mupirocin-resistant S. aureus
began appearing in the U.K. (3). Since then, such isolates
have been increasingly reported in many countries (4-6). In-
creasing numbers of mupirocin-resistant MRSA isolates have
been detected in patients who had previously received mu-
pirocin treatment, an observation cautioning against extend-
ed use of mupirocin ointment for eradication of MRSA nasal
carriage (5).
Mupirocin binds to the target enzyme, isoleucyl-tRNA
synthetase (IleS), in the vicinity of an ATP-binding subsite
and is a bifunctional inhibitor with characteristics of both iso-
leucine and ATP, i.e. an analogue of isoleucyladenylate (7).
Mupirocin resistance is phenotypically divided into two gro-
ups: low-level (minimal inhibition concentration [MIC]=8
to 256  g/mL) and high-level (MIC ≥512  g/mL) (8). High-
level resistance is mediated by a plasmid containing the ileS-
2 gene that encodes a novel isoleucyl-tRNA synthetase en-
zyme, whereas low-level resistance usually results from alter-
ation of the native IleS as a consequence of spontaneous muta-
tions in the ileS gene (8, 9). Since low-level mupirocin resis-
tance is more prevalent among clinical isolates (10), concerns
about treatment failure for nasal decolonization of MRSA are
increasing (11). 
Previous studies revealed the presence of molecular hetero-
geneity of mutations in the ileS gene among clinical isolates
and low-level mupirocin resistant MRSA strains selected in
vitro (12, 13). These studies reported that the V588F muta-
tion affecting the Rossman fold could interact directly with
mupirocin, causing emergence of low-level mupirocin resis-
tance (12). Notably, this mutation was not absolutely neces-
sary for the development of low-level mupirocin resistance,
and the V631F mutation was found to have effects similar
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Molecular Analysis of Isoleucyl-tRNA Synthetase Mutations in Clinical
Isolates of Methicillin-Resistant Staphylococcus aureus with Low-Level
Mupirocin Resistance
Emergence and spread of low-level mupirocin resistance in staphylococci have been
increasingly reported in recent years. The aim of this study was to characterize mis-
sense mutations within the chromosomal isoleucyl-tRNA synthetase gene (ileS)
among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) with
low-level mupirocin resistance. A total of 20 isolates of MRSA with low-level mupiro-
cin resistance (minimal inhibitory concentration, 16-64  g/mL) were collected from
79 patients in intensive care units for six months. The isolates were analyzed for
isoleucyl-tRNA synthetase (IleS) mutations that might affect the binding of mupirocin
to the three-dimensional structure of the S. aureus IleS enzyme. All isolates with
low-level mupirocin resistance contained the known V588F mutation affecting the
Rossman fold, and some of them additionally had previously unidentified mutations
such as P187F, K226T, F227L, Q612H, or V767D. Interestingly, Q612H was a novel
mutation that was involved in stabilizing the conformation of the catalytic loop con-
taining the KMSKS motif. In conclusion, this study confirms that molecular hetero-
geneity in ileS gene is common among clinical MRSA isolates with low-level mupirocin
resistance, and further study on clinical mutants is needed to understand the struc-
tural basis of low-level mupirocin resistance.
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to those of V588F on the structure IleS. Although V588F and
V631F clearly play a role in low-level mupirocin resistance,
it is unknown whether these mutations represent the full spec-
trum of IleS mutations that give rise to low-level mupirocin
resistance.
In this study, we examined the ileS gene for molecular het-
erogeneity in low-level mupirocin resistant MRSA strains
isolated from patients in intensive care units (ICUs), and ana-
lyzed how individual amino acid mutations affect the crystal
structure of the complex of S. aureus IleS with mupirocin. 
MATERIALS AND METHODS
Bacterial isolates
A total of 79 MRSA isolates were consecutively collected
from clinical cultures taken from patients in ICUs in a ter-
tiary care hospital from November 2003 to April 2004. The
specimens originated from blood, gastric juice, pus, skin, cen-
tral venous catheter tip, sputum, stool, swab, tracheal tip,
urine, and wounds. Isolates from one patient that were recov-
ered from different cultures were included only once. The
strains were stored in brain-heart infusion broth plus 20%
glycerol at -70℃until studied.
MRSA detection and mupirocin susceptibility
MRSA isolates were identified by the standard disk diffu-
sion method (14) and mecA was detected by polymerase chain
reaction (PCR). The primer pair used was MecA1 (5′ - ATG
CTA AAG TTC AAA AGA GTA TTT ATA A) and MecA2
(5′ -TGA TGA TTC TAT TGC TTT TAA GTC), yielding
a 400-bp product. MICs of mupirocin were determined by
a standardized agar dilution method in Mueller-Hinton agar
(Oxoid, Basingstoke, United Kingdom) with inocula in Mue-
ller-Hinton agar (Oxoid) of 106 CFU per spot. After 24 hr
of incubation at 37℃, the MIC was deemed the lowest con-
centration of antibiotic that prevented visible colonial growth.
MIC determination was evaluated according to the Clinical
and Laboratory Standards Institute (CLSI, formerly NCCLS)
guidelines (15). S. aureus ATCC 29213 was used as the con-
trol for the susceptibility test.
PCR amplification and sequencing of the ileS gene
To overcome the difficulty of long-PCR amplification of
the 3,044 bp- ileS gene sequence, we selected three parts of
the gene to be amplified which might contain the potential
mutations related to mupirocin resistance based on previous
studies (12, 13) and the three-dimensional structure of the IleS
enzyme active site. Three primer pairs were designed from
the S. aureus ileS gene (GenBank accession number X74219);
one pair was Smr1 (5′ -ATA AAG GTA AAA AGC CAG
TTT ATT GGT) and Smr2 (5′ -TAA TCG CAA CAT TTG
ATG GAA TTG TC) for the fragment of 200 bp (nt 450 to
650), the second was Mrm1 (5′ -TCC CAG CAG ATA TGT
ATT TAG AAG GT) and Mrm2 (5′ -AAC CAC TTG GTC
AGG TAC AAT CAC A) for the fragment of 450 bp (nt 800
to 1,250), and the third was Lmr1 (5′ -GTA AAT CTT TAG
GTA ATG TGA TTG TAC) and Lmr2 (5′ -TCT TCT TTA
ACA TGT GGT GTA TGA GA) for the fragment of 690 bp
(nt 1,730 to 2,420). Genomic DNA was prepared, and the ileS
gene fragments were amplified by PCR, as previously described
(12). PCR products were purified with QIAquick-spin PCR
purification kit (Qiagen, GmbH, Germany) and sequenced by
Bioneer Corporation (Daejeon, Korea). To detect the ileS-2 gene
conferring high-level mupirocin resistance, a 410-bp region in
the ileS-2 gene was amplified using another primer pair Mup1
(5′ -TAT ATT ATG CGA TGG AAG GTT GG) and Mup2
(5′ -AAT AAA ATC AGC TGG AAA GTG TTG) (10).
Structural analysis of IleS mutations
To better understand the interactions of IleS with mupirocin,
we used the crystal structure of IleS from S. aureus (Protein
Data Bank code: 1FFY) (16).
Pulsed-field gel electrophoresis (PFGE)
Chromosomal DNA for the SmaI restriction digest was
purified from 20 clinical MRSA isolates with low-level mupi-
rocin resistance as described previously (17). Electrophoresis
was performed with the GeneNavigatorTM‚ System (GE Heal-
thcare U.K. Ltd. Buckinghamshire, United Kingdom) at 130
V and at 16℃; 5 sec pulse time for 4 hr, 25 sec pulse time
for 6 hr, 45 sec pulse time for 20 hr, and 75 sec pulse time
for 6 hr. Total running time was 36 hr. PFGE  ladder* (New
England Biolabs Inc.) was used to provide molecular size mar-
kers. After staining with ethidium bromide, the band pat-
terns were compared using the criteria for bacterial strain
typing (18).
RESULTS
Isolation of clinical MRSA strains with low-level mupirocin
resistance
We isolated a total of 79 MRSA strains from patients in
ICUs in our hospital for the six-month study period. The iso-
lation rate of MRSA strains was approximately 75%. MRSA
isolates were mostly recovered from sputum cultures. Deter-
mination of MICs of mupirocin by the agar dilution method
revealed that twenty strains (Kua 1 to 20) (25.3% of total
isolates) displayed low-level mupirocin resistance from 16  g/
mL to 64  g/mL (Table 1). There were no MRSA isolates with
high-level mupirocin resistance.Identification of missense mutations in the ileS gene se-
quence in clinical MRSA isolates
To identify missense mutations that might contribute to
the low-level mupirocin resistance phenotype, we compared
the sequences of the ileS gene fragments amplified from 49
MRSA isolated from patients in ICUs, including 20 low-level
mupirocin resistance and 29 mupirocin-susceptible isolates,
with the published S. aureus ileS gene sequence (GenBank
accession no. X74219). We identified six missense mutations,
P187F, K226T, F227L, V588F, Q612H, and V767D, in the
strains with low-level mupirocin resistance. Those were not
identified in any of the mupirocin susceptible MRSA isolates.
Except for V588F, none of these mutations have been report-
ed previously. The V588F and Q612H mutations are locat-
ed near the Rossman fold motif, whereas the others are locat-
ed outside this motif. All of the strains with low-level mupi-
rocin resistance possessed the V588F, and some of them had
an additional one to three other mutations (Table 2, 3). An
A213D mutation was identified in all 49 strains analyzed,
irrespective of the MIC level of mupirocin resistance. Addi-
tionally, we identified various null mutations (T594C, A602C,
A643T, A685C and T1679C) that were present only in the
ileS genes of low-level mupirocin-resistant strains and some
(T1701C, T1974C, T1980C, T1995C and T2031G) that
were present in both mupirocin-resistant and -susceptible
strains (data not shown).
Structural analysis of amino acid mutations
To better understand the significance of the novel mutations,
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MIC ( g/mL) No. of isolate (%) Remark
<8 59 (74.7%) Susceptible
16 1 (1.2%)
32 13 (16.5%) Low-level resistant
64 6 (7.6%)
>256 0 (0%) High-level resistant
Total 79  (100%)
Table 1. Distribution of mupirocin MICs among MRSA isolates
from 79 patients in ICUs during November 2003 through April
2004
20 (25.3%)
Strain Source MIC ( g/mL) PFGE pattern
Kua 1 Wound 32 A1
Kua 2 Sputum 64 A
Kua 3 Sputum 32 A
Kua 4 Sputum 64 B
Kua 5 Sputum 64 B
Kua 6 Sputum 64 B
Kua 7 Sputum 64 A
Kua 8 Sputum 32 C
Kua 9 Sputum 32 C
Kua 10 Sputum 32 C
Kua 11 Sputum 32 C
Kua 12 Tracheal aspirate 32 D
Kua 13 Sputum 32 C
Kua 14 Sputum 32 D
Kua 15 Sputum 32 D
Kua 16 Sputum 32 E
Kua 17 Sputum 32 C
Kua 18 Tracheal aspirate 32 C
Kua 19 Urine 16 A
Kua 20 Sputum 64 C
Table 2. Mupirocin MICs and PFGE patterns of 20 MRSA iso-
lates with low-level mupirocin resistance 
P, Proline; F, Phenylalanine; K, Lysine; T, Threonine; L, Leucine; V, valine;
Q, glutamine; H, histidine; D, Aspartic acid.
Mutation identified  Isolates (%) containing individual mutation
P187F Kua 4-12, 14, 15, 19 (60)
K226T Kua 3 (5)
F227L Kua 3 (5)
V588F Kua 1-20 (100)
Q612H Kua 8-11, 13-15, 17, 18, 20 (50) 
V767D Kua 1 (5)
Table 3. Heterogeneity of IleS mutations among 20 MRSA iso-
lates with low-level mupirocin resistance
Fig. 1. Structure of IleS from S. aureus Oxford. Distribution of mu-
tated residues identified from MRSA isolates with low-level mupiro-
cin resistance. (A) Overall IleS structure showing bound tRNA
Ile
(violet) and mupirocin (slate/red) (22). The backbone fold of IleS
is shown as a ribbon, with individual sites of mutation highlighted
displaying 6 residues’ side chains (red) and sequence numbers,
and yellow-colored structure with the Q612H mutation. (B) Enlarged
view of the beta-helix region adjacent to the Rossman fold and
residues 588 and 612. Note that the Q612H mutation has poten-
tial to interact with mupirocin. Q612 sits close to the core of IleS
Rossman fold motif (yellow/blue), where it forms a water-bridged
hydrogen bond with the side chain of D635 (arrow).
V767
V588
D635
water
Q612
S. aureus 591 603 GEGKKMSKSLGNV
Q612
V588 P187
F226
F227
mupirocin
mupirocin
A
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we used a computer program to superimpose them on the
crystal structure of the S. aureus IleS. With the exception of
V588F, all the missense mutations we identified in this study
are novel mutations. Two of them, V588F and Q612H, are
located near the Rossman fold motif, and the others are locat-
ed outside (Fig. 1A). Because V588 is located in a hydropho-
bic pocket that interacts directly with the fatty acid side chain
of mupirocin, mutation of this residue causes steric repulsion
to mupirocin. The Q612H mutation has potential to inter-
act with mupirocin. Q612 sits close to the core of IleS Ross-
man fold motif, where it forms a water-bridged hydrogen
bond with the side chain of D635 (Fig. 1B). Since it is located
at about 15 Å from the binding site of mupirocin, it is not
clear how the Q612H mutation could directly affect the inter-
action with mupirocin. The Q612H mutation appeared to
affect the catalytic loop configuration during substrate bind-
ing, thus leading to the differences in the inhibitory activity
of mupirocin.
Contributions of other mutations to mupirocin resistance
are unlikely to be as direct as that of V588F, and these muta-
tions might indirectly affect the interaction with mupirocin.
K226T and F227L are on the outer surface adjacent to the
tRNA molecule about 20 Å from the editing active site.
P187F, about 20 Å distant from the 3′ end of the tRNA, is
located near the CP2 domain. In contrast, V767D lies in the
interior surface of the cylindrical central helical domain of
the IleS, distal to the tRNA binding site. 
Characterization of low-level mupirocin resistant MRSA
isolates by PFGE analysis
To determine whether the emergence of low-level mupirocin
resistant MRSA isolates in ICUs was derived from a clone
with epidemic potential, we analyzed the genetic relatedness
of 20 MRSA isolates with low-level mupirocin resistance by
PFGE analysis. Related isolates were identified by SmaI mac-
rorestriction patterns. All twenty isolates were separated into
five PFGE types (A, B, C, D, and E) and a subtype, A1 (Fig.
2). PFGE type A was considered an endemic clone, since it
was isolated persistently from the beginning to the end of
the six-month study. Other clones (PFGE types, B, C, D and
E) had colonized or infected patients for a few months and,
once introduced into the ICUs, spread among patients. Inter-
estingly, PFGE types were not associated with individual mu-
tations of IleS enzymes. Isolates with the identical PFGE pat-
tern contained different IleS mutations, and isolates from dif-
ferent PFGE types contained the same IleS mutations. Nota-
bly, the Q612H mutation was only identified in PFGE types
C and D (Table 2). 
DISCUSSION
In this study, we investigated the molecular heterogeneity
of IleS mutations in low-level mupirocin resistant MRSA
strains isolated from patients in ICUs. We characterized the
identified mutations by superimposition on the crystal struc-
ture of the S. aureus IleS. We identified six missense mutations
(P187F, K226T, F227L, V588F, Q612H, and V767D) that
were only present among MRSA isolates with low-level mupi-
rocin resistance. Based on previously reported ileS gene muta-
tions associated with low-level mupirocin resistance in MRSA
strains originating in Europe, North America (12), and Japan
(13), five of the six missense mutations identified in this study
are novel. In particular, the Q612H is a novel mutation that
seems to be involved in stabilizing the conformation of cat-
alytic loop containing the KMSKS motif. Until now, only
amino acid substitutions at two sites (V588F and V631F)
in IleS have been detected in clinical S. aureus isolates express-
ing low-level mupirocin resistance (12, 13). Whether these
are the only lleS mutations that confer mupirocin resistance
is unknown. The V588F mutation is known to disrupt the
hydrophobic pocket within the mupirocin-binding Rossman
fold possessing the consensus HXGX and GXKMSKS motifs,
and the V631F substitution has an effect similar to that of
V588F. Our results suggest that the mutations located at some
distance from the KMSKS motif could have a significant effect
on the conformational changes of IleS, leading to the low-
level mupirocin resistance.
A recent study showed that other novel mutations linked
to emergence of mupirocin resistance (G593V, R816C, H67Q,
and F563L in various combinations) could be generated from
laboratory S. aureus isolates with incremental increases in resis-
tance after repeated exposure to increasing concentrations of
mupirocin (19). However, in our study we only detected the
V588F mutation and failed to detect either the novel muta-
Fig. 2. Representative PFGE patterns of Sma I macrorestriction frag-
ments of genomic DNA of MRSA strains with low-level mupirocin
resistance isolated from patients in ICUs. Lane 1,  ladder marker; lane
2 to lane 7 show PFGE patterns A0, A1, B, C, D, and E, respectively.
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tions that originated from the laboratory stains or other IleS
mutations including the V631F mutation identified in pre-
vious clinical isolates with low-level mupirocin resistance
(12, 13). On the other hand, the contributions of the other
four mutations newly identified in this study are unlikely to
be those of V588F or Q612H, and further studies on these
mutations are needed. These findings confirm that the molec-
ular heterogeneity of S. aureus IleS mutations are common
among clinical isolates of MRSA with low-level mupirocin
resistance.
Our study has revealed an unexpectedly high rate (25.3%)
of isolation of MRSA strains with low-level mupirocin resis-
tance, compared to rates reported previously in Japan (20) or
in Korea (10). This probably stems from the targeted surveil-
lance of patients in ICUs where MRSA is endemic. The PFGE
analysis revealed different PFGE patterns among MRSA iso-
lates with low-level mupirocin resistance. Several isolates with
identical PFGE patterns contained different IleS mutations,
whereas isolates from different PFGE types contained the
same IleS mutations. The Q612H mutation was identified
only in PFGE types C and D. Therefore, it is likely that indi-
vidual IleS mutations might occur in several PFGE clones.
It is also possible that a few of PFGE clones with the same
IleS mutation were spread. It is not known whether the pati-
ents in the ICUs were exposed to mupirocin.
Although low-level mupirocin resistance in S. aureus is more
prevalent in clinical isolates than high-level resistance (4, 10,
20), its clinical significance is still unknown. It is possible,
however, that the increasing frequency of IleS mutants might
cause failure for nasal decolonization of MRSA carriers (4).
Alternatively, it might suggest that a low fitness cost is asso-
ciated with the high prevalence of low-level mupirocin resis-
tant strains (19). 
In conclusion, molecular heterogeneity of IleS mutations
conferring low-level mupirocin resistance is commonly pre-
sent among clinical MRSA strains in ICUs in a setting where
MRSA is endemic. In addition to the V588F, the novel Q612H
mutation is expected to be linked to low-level mupirocin
resistance. Further study of several IleS structures from mutant
clinical isolates is necessary to better understand the structural
basis of low-level mupirocin resistance.
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